Given the rarity of ROS1 rearrangements in NSCLC, screening of tumours by IHC may allow unnecessary FISH analysis in ROS1-negative cases to be avoided and thus dramatically reduce the cost of testing. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.